Comparison of the BD Veritor System for Flu A+B with the Alere BinaxNOW Influenza A&amp;B Card for Detection of Influenza A and B Viruses in Respiratory Specimens from Pediatric Patients

Hassan, Ferdaus; Nguyen, Ashley; Formanek, Ashley; Bell, James J.; Selvarangan, Rangaraj

doi:10.1128/jcm.02484-13

Cited by 36 publications

(24 citation statements)

References 19 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have demonstrated similar results and conclusions, and some of these are referenced in the bibliography (Dunn et al, 2014;Hassan et al, 2014). Moreover, no false positive results have been obtained among all tested nasopharyngeal swab specimens.…”

Section: Discussionsupporting

confidence: 60%

Evaluation of the Alere i Influenza A&B assay for rapid identification of influenza A and influenza B viruses

Chiarella

Culebras

Fuentes‐Ferrer

et al. 2016

Journal of Medical Microbiology

View full text Add to dashboard Cite

The Alere i Influenza A&B assay is a novel isothermal nucleic acid amplification assay capable of detecting and differentiating influenza A and B viruses in approximately 15 min with minimal hands-on time. This study was conducted in order to assess the performance of the Alere i Influenza A&B assay compared to molecular techniques, considered to be gold standard methods, to evaluate the results. A total of 119 nasopharyngeal swabs collected from inpatients with influenza-like illness were included in the study using both archived and prospectively collected samples from adults and children. Prospectively collected samples were also compared to the Alere BinaxNOW ® Influenza A & B Card. The overall sensitivity for detection of influenza A and B viruses compared to those of molecular techniques were 65.96 % and 53.33 % respectively, while the specificity was 98.51 % and 95.96 %.

show abstract

Section: Discussionsupporting

confidence: 60%

Evaluation of the Alere i Influenza A&B assay for rapid identification of influenza A and influenza B viruses

Chiarella

Culebras

Fuentes‐Ferrer

et al. 2016

Journal of Medical Microbiology

View full text Add to dashboard Cite

show abstract

“…The increased diagnostic yield over rapid influenza virus antigen detection tests could range from 10 to 30% (4,14), but direct comparisons of the performance characteristics of these tests are lacking. Future studies should focus on establishing the true increase in diagnostic yield and the clinical and financial impacts of implementing point-ofcare molecular diagnostics for influenza.…”

Section: Discussionmentioning

confidence: 99%

“…The chromatographic immunoassays typically have suffered from moderate to low sensitivity; however, recent improvements in test chemistries and instrument readout of results have improved their performance characteristics (1)(2)(3)(4). Currently, there are two CLIA-waived, FDA-cleared nucleic acid amplification tests designed to be performed as point-of-care tests by nonlaboratory personnel, the Alere i (Alere, Scarborough, MA) and cobas Liat (Roche Diagnostics, Indianapolis IN) influenza A and B tests.…”

mentioning

confidence: 99%

Direct Comparison of Alere i and cobas Liat Influenza A and B Tests for Rapid Detection of Influenza Virus Infection

2016

View full text Add to dashboard Cite

We compared two rapid, point-of care nucleic acid amplification tests for detection of influenza A and B viruses (Alere i [Alere] and cobas Liat [Roche Diagnostics]) with the influenza A and B virus test components of the FilmArray respiratory panel (BioFire Diagnostics) using 129 respiratory specimens collected in universal viral transport medium (80 influenza A virus and 16 influenza B virus positive) from both adult and pediatric patients. The sensitivities of the Alere test were 71.3% for influenza A virus and 93.3% for influenza B virus, with specificities of 100% for both viruses. The sensitivities and specificities of the Liat test were 100% for both influenza A and B viruses. The poor sensitivity of the Alere test for detection of influenza A virus was likely due to a study set that included many low-positive samples that were below its limit of detection. Influenza is a significant cause of morbidity and mortality worldwide. Although the diagnosis is often made by clinical signs and symptoms alone, laboratory testing may be needed to guide antiviral therapy, determine isolation precautions, and provide epidemiologic data, since many different respiratory viruses can cause influenza-like illness. The laboratory diagnosis of influenza has evolved from the use of culture and antigen detection tests to nucleic acid amplification tests that are now considered the new gold standard.Until recently, point-of-care diagnostic testing has been limited to rapid antigen tests based on chromatographic immunoassay technology designed in simple-to-use formats with results available in Ͻ30 min. The chromatographic immunoassays typically have suffered from moderate to low sensitivity; however, recent improvements in test chemistries and instrument readout of results have improved their performance characteristics (1-4). Currently, there are two CLIA-waived, FDA-cleared nucleic acid amplification tests designed to be performed as point-of-care tests by nonlaboratory personnel, the Alere i (Alere, Scarborough, MA) and cobas Liat (Roche Diagnostics, Indianapolis IN) influenza A and B tests. These tests hold promise to significantly improve near-patient diagnostic testing for influenza and may facilitate true practice changes in how clinicians manage these patients.The Alere test is semiautomated and uses an isothermal nicking enzyme amplification reaction and fluorescently labeled molecular beacons to amplify and detect a region of the polymerase basic protein 2 gene in influenza A virus, a region of the polymerase acid protein gene in influenza B virus, and an internal control in less than 15 min (5). The Alere test is intended to be used for direct nasal swabs (CLIA complexity, waived) and for nasal and nasopharyngeal swabs eluted in viral transport medium (CLIA complexity, moderate). The Alere test has reported sensitivities and specificities of from 80 to 99.3% and from 62.5 to 100%, respectively, for detection of influenza A virus and from 45.2 to 97.6% and 53.6 to 100%, respectively, for detection of influenza B vir...

show abstract

“…Once an EV-D68-specific RT-PCR method was developed, the remaining samples were tested by RT-PCR only at CMH. Total RNA was extracted [24] and tested per CDC protocol with minor modification of the probe to use 5-Cy5 dye [25]. All primers and probes were purchased from IDT DNA Inc (Coralville, IA).…”

Section: Virologic Testingmentioning

confidence: 99%

Severe enterovirus 68 respiratory illness in children requiring intensive care management

Schuster¹,

Miller²,

Selvarangan³

et al. 2015

Journal of Clinical Virology

Self Cite

View full text Add to dashboard Cite

Comparison of the BD Veritor System for Flu A+B with the Alere BinaxNOW Influenza A&B Card for Detection of Influenza A and B Viruses in Respiratory Specimens from Pediatric Patients

Cited by 36 publications

References 19 publications

Evaluation of the Alere i Influenza A&B assay for rapid identification of influenza A and influenza B viruses

Evaluation of the Alere i Influenza A&B assay for rapid identification of influenza A and influenza B viruses

Direct Comparison of Alere i and cobas Liat Influenza A and B Tests for Rapid Detection of Influenza Virus Infection

Severe enterovirus 68 respiratory illness in children requiring intensive care management

Contact Info

Product

Resources

About